Cargando…

Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series

OBJECTIVE: To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine Pandemrix. DESIGN: Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohet, Catherine, Haguinet, François, Dos Santos, Gaël, Webb, Dave, Logie, John, LC Ferreira, Germano, Rosillon, Dominique, Shinde, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735133/
https://www.ncbi.nlm.nih.gov/pubmed/26823177
http://dx.doi.org/10.1136/bmjopen-2015-009264
_version_ 1782413024690176000
author Cohet, Catherine
Haguinet, François
Dos Santos, Gaël
Webb, Dave
Logie, John
LC Ferreira, Germano
Rosillon, Dominique
Shinde, Vivek
author_facet Cohet, Catherine
Haguinet, François
Dos Santos, Gaël
Webb, Dave
Logie, John
LC Ferreira, Germano
Rosillon, Dominique
Shinde, Vivek
author_sort Cohet, Catherine
collection PubMed
description OBJECTIVE: To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine Pandemrix. DESIGN: Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospital Episodes Statistics (HES) inpatient database. Analyses were conducted using the SCCS method for censored, perturbed or curtailed post-event exposure. PARTICIPANTS: Of the 184 transplant recipients having experienced at least one SOT rejection (liver, kidney, lung, heart or pancreas) during the study period from 1 October 2009 to 31 October 2010, 91 participants were included in the main analysis, of which 71 had been exposed to Pandemrix. MAIN OUTCOME MEASURES: Occurrence of SOT rejection during risk (30 and 60 days after any Pandemrix dose) and control periods. Covariates in the CPRD included time since transplantation, seasonal influenza vaccination, bacterial and viral infections, previous SOT rejections and malignancies. RESULTS: The relative incidence (RI) of rejection of any one of the five transplanted organs, adjusted for time since transplantation, was 1.05 (95% CI 0.52 to 2.14) and 0.80 (95% CI 0.42 to 1.50) within 30 and 60 days after vaccination, respectively. Similar estimates were observed for rejection of a kidney only, the most commonly transplanted organ (RI within 30 days after vaccination: 0.85 (95% CI 0.38 to 1.90)). Across various models and sensitivity analyses, RI estimates remained stable and within a consistent range around 1.0. CONCLUSIONS: These results suggest a reassuring safety profile for Pandemrix with regard to the risk of rejection in SOT recipients in England and contribute to inform the benefit–risk of AS03-adjuvanted pandemic influenza vaccines in transplanted patients in the event of future pandemics. TRIAL REGISTRATION NUMBER: NCT01715792.
format Online
Article
Text
id pubmed-4735133
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47351332016-02-09 Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series Cohet, Catherine Haguinet, François Dos Santos, Gaël Webb, Dave Logie, John LC Ferreira, Germano Rosillon, Dominique Shinde, Vivek BMJ Open Epidemiology OBJECTIVE: To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine Pandemrix. DESIGN: Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospital Episodes Statistics (HES) inpatient database. Analyses were conducted using the SCCS method for censored, perturbed or curtailed post-event exposure. PARTICIPANTS: Of the 184 transplant recipients having experienced at least one SOT rejection (liver, kidney, lung, heart or pancreas) during the study period from 1 October 2009 to 31 October 2010, 91 participants were included in the main analysis, of which 71 had been exposed to Pandemrix. MAIN OUTCOME MEASURES: Occurrence of SOT rejection during risk (30 and 60 days after any Pandemrix dose) and control periods. Covariates in the CPRD included time since transplantation, seasonal influenza vaccination, bacterial and viral infections, previous SOT rejections and malignancies. RESULTS: The relative incidence (RI) of rejection of any one of the five transplanted organs, adjusted for time since transplantation, was 1.05 (95% CI 0.52 to 2.14) and 0.80 (95% CI 0.42 to 1.50) within 30 and 60 days after vaccination, respectively. Similar estimates were observed for rejection of a kidney only, the most commonly transplanted organ (RI within 30 days after vaccination: 0.85 (95% CI 0.38 to 1.90)). Across various models and sensitivity analyses, RI estimates remained stable and within a consistent range around 1.0. CONCLUSIONS: These results suggest a reassuring safety profile for Pandemrix with regard to the risk of rejection in SOT recipients in England and contribute to inform the benefit–risk of AS03-adjuvanted pandemic influenza vaccines in transplanted patients in the event of future pandemics. TRIAL REGISTRATION NUMBER: NCT01715792. BMJ Publishing Group 2016-01-28 /pmc/articles/PMC4735133/ /pubmed/26823177 http://dx.doi.org/10.1136/bmjopen-2015-009264 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
Cohet, Catherine
Haguinet, François
Dos Santos, Gaël
Webb, Dave
Logie, John
LC Ferreira, Germano
Rosillon, Dominique
Shinde, Vivek
Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title_full Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title_fullStr Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title_full_unstemmed Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title_short Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
title_sort effect of the adjuvanted (as03) a/h1n1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in england: a self-controlled case series
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735133/
https://www.ncbi.nlm.nih.gov/pubmed/26823177
http://dx.doi.org/10.1136/bmjopen-2015-009264
work_keys_str_mv AT cohetcatherine effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT haguinetfrancois effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT dossantosgael effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT webbdave effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT logiejohn effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT lcferreiragermano effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT rosillondominique effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries
AT shindevivek effectoftheadjuvantedas03ah1n12009pandemicinfluenzavaccineontheriskofrejectioninsolidorgantransplantrecipientsinenglandaselfcontrolledcaseseries